Cargando…
Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity
Left ventricular (LV) mass loss is prevalent in doxorubicin (DOX)-induced cardiotoxicity and is responsible for the progressive decline of cardiac function. Comparing with the well-studied role of cell death, the part of cardiomyocyte atrophy (CMA) playing in the LV mass loss is underestimated and t...
Autores principales: | Chen, De-Shu, Yan, Jing, Yang, Ping-Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913904/ https://www.ncbi.nlm.nih.gov/pubmed/35282350 http://dx.doi.org/10.3389/fcvm.2022.812578 |
Ejemplares similares
-
Review on the Role of Epigenetic Modifications in Doxorubicin-Induced Cardiotoxicity
por: Kumari, Himani, et al.
Publicado: (2020) -
Exploring the Mechanism of Danshensu in the Treatment of Doxorubicin-Induced Cardiotoxicity Based on Network Pharmacology and Experimental Evaluation
por: Qi, Jia-ying, et al.
Publicado: (2022) -
Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity
por: Singh, Manrose, et al.
Publicado: (2022) -
Exercise Training Preserves Myocardial Strain and Improves Exercise Tolerance in Doxorubicin-Induced Cardiotoxicity
por: Gomes-Santos, Igor L., et al.
Publicado: (2021) -
Identification of novel biomarkers involved in doxorubicin-induced acute and chronic cardiotoxicity, respectively, by integrated bioinformatics
por: Qian, Hongyan, et al.
Publicado: (2023)